Clinical Trials Browser

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT02795182 2022-07-01

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Phase 1 Completed

75 enrolled 17 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence

NCT05277675 2022-03-14

RANT

Phase NA Unknown

160 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT04981665 2022-01-05

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Phase 2 Unknown

50 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT04539444 2021-08-02

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Phase 2 Unknown

10 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

Clinical Trials

EpiRev-NKT

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

RATIONALE-309

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

RANT

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma